Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $26.96M (cash outflow) rose 91.6% year over year, ahead of the +15.4% change in trailing-twelve-month net income. Sequentially, it fell 7.3% from the prior quarter.

Context

  • Net income amounted to 97.9% of revenue in FY2025, up 39.4 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 8 analysts of -$83.45M (+26.9%) for the fiscal year ending Dec 2026, a step up from the -18.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$26.96M-7.3% QoQ
Last fiscal yearDec 2025
-$65.78M-18.7% YoY
LTMMar 2026
-$78.67M+15.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+91.6%+208.7%+117.1 pp
1 year-18.7%+26.9%+45.6 pp
3-year CAGR—+10.5%—
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(65.78M) USD
Year-over-year change
+18.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.4% is the 6th highest of 10, against a peer median of +21.5%.
  • Net income amounts to 173.5% of revenue for ARCT, versus a peer median of 216.5%.
ARCT Competitors
Net Income for ARCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$442.72M USD-23.4%—676.0%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$209.38M USD-18.9%+0.2%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$169.52M USD+21.5%+11.0%—
ABUSArbutus Biopharma CorporationLTM Mar 2026$160.72M USD+309.9%-21.6%84.0%
VALNValneva SELTM Mar 2026€146.23M EUR+81.9%-7.0%93.5%
SLNSilence Therapeutics plcLTM Mar 2026$145.44M USD—+20.7%15782.6%
NVAXNovavax, Inc.LTM Mar 2026$87.84M USD-118.3%—14.7%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$84.93M USD-12.0%-32.8%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$78.67M USD+15.4%—173.5%
PRQRProQR Therapeutics N.V.LTM Mar 2026€45.62M EUR+51.2%-14.2%339.4%
BNTCBenitec Biopharma Inc.LTM Mar 2026$41.54M USD+56.8%+27.7%—
Peer median (excluding ARCT) —+21.5%-3.4%216.5%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
Deferred Income Tax00000
Stock-Based Compensation28.92M30.61M34.65M37.99M25.41M
Change in Working Capital32.63M(12.56M)7.38M(20.81M)(39.2M)
Accounts Receivables(1.24M)603K(29.3M)28.09M(1.59M)
Inventory00000
Accounts Payables(769K)(3.11M)(2.24M)1.92M(2.96M)
Other Working Capital34.64M(10.05M)38.92M(50.81M)(34.65M)
Other Non-Cash Items5.9M3.06M(33.36M)471K2.28M
Operating Cash Flow(135.04M)31.99M(18.1M)(59.75M)(74.27M)
Capital Expenditures(3.41M)(7.73M)(2.9M)(648K)(230K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(3.41M)(7.73M)(2.9M)(648K)(230K)
Debt Repayment46.6M(5M)(27.36M)00
Common Stock Issued515K411K609K682K13.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities902K1.73M2.67M4.74M0
Financing Cash Flow48.02M(2.86M)(24.09M)5.42M13.38M
Effect of Forex Changes00000
Net Change in Cash(90.43M)21.41M(45.09M)(54.98M)(61.12M)
Free Cash Flow(138.45M)24.27M(21M)(60.4M)(74.27M)

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.